| Identification | Back Directory | [Name]
KDU691 | [CAS]
1513879-19-0 | [Synonyms]
KDU691
KDU691 >=98% (HPLC)
KDU691;KDU-691;KDU 691;1513879-19-0
Imidazo[1,2-a]pyrazine-6-carboxamide, N-(4-chlorophenyl)-N-methyl-3-[4-[(methylamino)carbonyl]phenyl]- | [Molecular Formula]
C22H18ClN5O2 | [MOL File]
1513879-19-0.mol | [Molecular Weight]
419.86 |
| Chemical Properties | Back Directory | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:PBS (pH 7.2) (1:9):0.1(Max Conc. mg/mL);0.24(Max Conc. mM)
Ethanol:10.0(Max Conc. mg/mL);23.82(Max Conc. mM) | [form ]
A crystalline solid | [pka]
14.59±0.46(Predicted) | [color ]
White to off-white | [InChI]
1S/C22H18ClN5O2/c1-24-21(29)15-5-3-14(4-6-15)19-11-26-20-12-25-18(13-28(19)20)22(30)27(2)17-9-7-16(23)8-10-17/h3-13H,1-2H3,(H,24,29) | [InChIKey]
TYMFFISSODJRDV-UHFFFAOYSA-N | [SMILES]
O=C(N(C1=CC=C(Cl)C=C1)C)C(N=C2)=CN3C2=NC=C3C4=CC=C(C(NC)=O)C=C4 |
| Hazard Information | Back Directory | [Description]
KDU691 is an antimalarial compound.1 It inhibits recombinant P. vivax phosphatidylinositol 4-kinase (PI4K) with an IC50 value of 1.5 nM. KDU691 is selective for P. vivax PI4K over recombinant human PI4KβIII and PI3Kα, -β, -γ, and -δ (IC50s = 7.9, 8.8, 2.4, 8, and 3.4 μM, respectively), as well as VPS34 (IC50 = >9.7 μM) and 36 additional kinases in a panel of lipid and protein kinases (IC50s = >10 μM). It is active against P. falciparum and P. yoelii schizonts (IC50s = 0.06 and 0.04 μM, respectively), as well as P. cynomolgi schizonts and hypnozoites (IC50s = 0.11 and 0.2 μM, respectively).2 KDU691 completely prevents, but does not eradicate established, P. cynomolgi infection in rhesus monkeys when administered at a dose of 20 mg/kg.3 | [Uses]
KDU691, is a PI4K inhibitor. | [in vivo]
During the 5 days of dosing, no major weight changes are observed in the animals that receive KDU691 as prophylactic treatment (group 691-proph). From the fourth day of dosing, the animals that are treated with KDU691 show a transient yellow skin color. The KDU691 radical-cure group (group 691-RC) becomes blood-stage positive again at 31.8 days p.i. (range, 31 to 32 days). Clinical chemistry analysis of the group 691-RC monkeys reveals that bilirubin levels accumulate during the 5-day radical-cure treatment with KDU691[2]. | [IC 50]
Plasmodium | [storage]
Store at -20°C | [References]
[1] CASE W. MCNAMARA. Targeting Plasmodium PI(4)K to eliminate malaria[J]. Nature, 2013, 504 7479: 248-253. DOI: 10.1038/nature12782
[2] BIN ZOU*. Lead Optimization of Imidazopyrazines: A New Class of Antimalarial with Activity on Plasmodium Liver Stages[J]. ACS Medicinal Chemistry Letters, 2014, 5 8: 947-950. DOI: 10.1021/ml500244m
[3] A. ZEEMAN. PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites[J]. Antimicrobial Agents and Chemotherapy, 2016, 60 1: 2858-2863. DOI: 10.1128/aac.03080-15 |
|
| Company Name: |
Twochem Co.Ltd.
|
| Tel: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|